What Is The Biomedical Waste
What Is The Biomedical Waste
Bio-medical wate means “any solid and /or liquid waste which is generated during the
diagnosis, treatment or immunization of human beings or animals.
Biomedical waste poses hazard due to two principal reasons – the first is infectivity and
other toxicity.
sources
Source of
biomedical wastes
Minor Major
sources sources
Hazardous waste
Hazardous waste includes 10- 25% of the overall biomedical waste.
Biomedical waste poses hazard due to two principal reasons.
-Infectivity (15%-18%)
-Toxicity (5%-7%)
. foetus.
Pharmaceutical waste: waste containing pharmaceuticals; e.g. pharmaceuticals that are
expired or no longer needed; contaminated pharmaceuticals
(bottles, boxes).
Genotoxic waste: waste containing cytostatic drugs (often used in cancer therapy)/
Genotoxic chemicals.
Chemical waste: waste containing chemical substances e.g. laboratory regents; film
developer, disinfectants and solvents that are expired or on needed.
Waste with high content of heavy metals: batteries, broken thermometers, blood pressure .
. unsealed radionuclides.
Segregation
Proof container)
Disinfection policy
Disinfectant policy should be formulated by the “hospital infection control committee”,
who would then decide on the types of disinfectants to be used in their hospital. This
requires consultation between the microbiologist, infection control doctor, infection
control nurse, pharmacist, supplies officer and representative of medical, nursing and
domestic staff. The selection of a disinfectant depends on many factors such as:
Intended use of the disinfectant, whether for medical equipment, environment,
skin mucous membranes
Range of activity
Speed of action
Inactivation by organic material
Compatibility with items processed and processing equipment
Safety to the user
Stability
Cost.
Antibiotic policy
Formulation of an antibiotic policy is essential for every hospital. The reasons are:
1. It is a way of ensuring that patients receive appropriate therapy.
2. When the use of antibiotics is restricted, the appearance of resistant strains
will be delayed and thus incidence in the hospital is kept low.
3. Up-to-up information should be provided for the prescriber, and the
incidence of adverse reaction should be reduced by restricting the use of
certain potentially toxic agents.
4. Costs are reduced by controlling the use of expensive drugs.
The type of policy must be adapted to the needs of the staff, the type of patients and
organisms prevalent in the hospital or units. It must therefore be flexible, and, where necessary,
adapted to the needs of the individual units (e.g. burns and intensive care).